Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with
acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic
Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)